Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

CYP3A4 activity reduces the cytotoxic effects of okadaic acid in HepaRG cells.

Kittler K, Fessard V, Maul R, Hurtaud-Pessel D.

Arch Toxicol. 2014 Aug;88(8):1519-26. doi: 10.1007/s00204-014-1206-x.

PMID:
24504163
2.

Modulation of CYP3A4 activity alters the cytotoxicity of lipophilic phycotoxins in human hepatic HepaRG cells.

Ferron PJ, Hogeveen K, De Sousa G, Rahmani R, Dubreil E, Fessard V, Le Hegarat L.

Toxicol In Vitro. 2016 Jun;33:136-46. doi: 10.1016/j.tiv.2016.02.021.

PMID:
26956883
3.

Differences in metabolism of the marine biotoxin okadaic acid by human and rat cytochrome P450 monooxygenases.

Kolrep F, Hessel S, These A, Ehlers A, Rein K, Lampen A.

Arch Toxicol. 2016 Aug;90(8):2025-36. doi: 10.1007/s00204-015-1591-9.

PMID:
26374342
4.

The algal hepatoxoxin okadaic acid is a substrate for human cytochromes CYP3A4 and CYP3A5.

Guo F, An T, Rein KS.

Toxicon. 2010 Feb-Mar;55(2-3):325-32. doi: 10.1016/j.toxicon.2009.08.007.

5.

Analysis of the passage of the marine biotoxin okadaic acid through an in vitro human gut barrier.

Ehlers A, Scholz J, These A, Hessel S, Preiss-Weigert A, Lampen A.

Toxicology. 2011 Jan 11;279(1-3):196-202. doi: 10.1016/j.tox.2010.11.001.

PMID:
21093526
6.

Sertraline-induced potentiation of the CYP3A4-dependent neurotoxicity of carbamazepine: an in vitro study.

Ghosh C, Hossain M, Spriggs A, Ghosh A, Grant GA, Marchi N, Perucca E, Janigro D.

Epilepsia. 2015 Mar;56(3):439-49. doi: 10.1111/epi.12923.

7.

Embryotoxic effects of the marine biotoxin okadaic acid on murine embryonic stem cells.

Ehlers A, Stempin S, Al-Hamwi R, Lampen A.

Toxicon. 2010 Apr 1;55(4):855-63. doi: 10.1016/j.toxicon.2009.12.008.

PMID:
20026154
8.

Active elimination of the marine biotoxin okadaic acid by P-glycoprotein through an in vitro gastrointestinal barrier.

Ehlers A, These A, Hessel S, Preiss-Weigert A, Lampen A.

Toxicol Lett. 2014 Mar 3;225(2):311-7. doi: 10.1016/j.toxlet.2013.12.019.

PMID:
24374049
9.

Cytotoxicity of 3-(3,5-dichlorophenyl)-2,4-thiazolidinedione (DCPT) and analogues in wild type and CYP3A4 stably transfected HepG2 cells.

Frederick DM, Jacinto EY, Patel NN, Rushmore TH, Tchao R, Harvison PJ.

Toxicol In Vitro. 2011 Dec;25(8):2113-9. doi: 10.1016/j.tiv.2011.09.015.

10.

Human CYP3A4-introduced HepG2 cells: in vitro screening system of new chemicals for the evaluation of CYP3A4-inhibiting activity.

Araki N, Tsuruoka S, Wang N, Hasegawa G, Yanagihara H, Ando H, Omasa T, Enosawa S, Nagai H, Fujimura A.

Xenobiotica. 2008 Nov;38(11):1355-64. doi: 10.1080/00498250802468645.

PMID:
18846481
11.

Diarrhetic effect of okadaic acid could be related with its neuronal action: Changes in neuropeptide Y.

Louzao MC, Fernández DA, Abal P, Fraga M, Vilariño N, Vieytes MR, Botana LM.

Toxicol Lett. 2015 Sep 2;237(2):151-60. doi: 10.1016/j.toxlet.2015.06.004.

PMID:
26086426
12.

Studies on the role of metabolic activation in tyrosine kinase inhibitor-dependent hepatotoxicity: induction of CYP3A4 enhances the cytotoxicity of lapatinib in HepaRG cells.

Hardy KD, Wahlin MD, Papageorgiou I, Unadkat JD, Rettie AE, Nelson SD.

Drug Metab Dispos. 2014 Jan;42(1):162-71. doi: 10.1124/dmd.113.054817.

13.

Role of cytochrome P450 3A4 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor.

Chiba M, Hensleigh M, Nishime JA, Balani SK, Lin JH.

Drug Metab Dispos. 1996 Mar;24(3):307-14.

PMID:
8820421
14.

DNA breaks and cell cycle arrest induced by okadaic acid in Caco-2 cells, a human colonic epithelial cell line.

Traoré A, Baudrimont I, Ambaliou S, Dano SD, Creppy EE.

Arch Toxicol. 2001 Apr;75(2):110-7.

PMID:
11354906
15.

The structures of three metabolites of the algal hepatotoxin okadaic acid produced by oxidation with human cytochrome P450.

Liu L, Guo F, Crain S, Quilliam MA, Wang X, Rein KS.

Bioorg Med Chem. 2012 Jun 15;20(12):3742-5. doi: 10.1016/j.bmc.2012.04.046.

16.

In vitro metabolism of the cyanotoxin cylindrospermopsin in HepaRG cells and liver tissue fractions.

Kittler K, Hurtaud-Pessel D, Maul R, Kolrep F, Fessard V.

Toxicon. 2016 Feb;110:47-50. doi: 10.1016/j.toxicon.2015.11.007.

PMID:
26610396
17.

Drug-drug interation prediction between ketoconazole and anti-liver cancer drug Gomisin G.

Xiaoyang L, Chenming N, Chengqing L, Tao L.

Afr Health Sci. 2015 Jun;15(2):590-3. doi: 10.4314/ahs.v15i2.35.

18.

Inhibition and stimulation of intestinal and hepatic CYP3A activity: studies in humanized CYP3A4 transgenic mice using triazolam.

van Waterschoot RA, Rooswinkel RW, Sparidans RW, van Herwaarden AE, Beijnen JH, Schinkel AH.

Drug Metab Dispos. 2009 Dec;37(12):2305-13. doi: 10.1124/dmd.109.029397.

19.

Effects of triptolide on the pharmacokinetics of cyclophosphamide in rats: a possible role of cytochrome P3A4 inhibition.

Zhang XF, Liu J, Ye F, Ji SG, Zhang N, Cao RS, He L, Wu JC, Li XF.

Chin J Integr Med. 2014 Jul;20(7):534-9. doi: 10.1007/s11655-014-1710-0.

PMID:
24420925
20.

Supplemental Content

Support Center